Core Insights - Zhejiang Iwu Biological Technology Co., Ltd. has received approval from the National Medical Products Administration for its "Artemisia pollen prick solution," enhancing its product pipeline in the field of allergic disease diagnosis [1][2] - The approval of the new formulation signifies the company's commitment to innovation and its ability to navigate regulatory processes effectively [1][3] Company Developments - The newly approved product has a total allergen activity of 3500 DU/ml and a packaging volume of 2 ml, complementing the company's existing skin prick diagnostic products [1] - The company has achieved significant financial growth, reporting a revenue of 853 million yuan for the first three quarters of 2025, a year-on-year increase of 16.86%, and a net profit of 345 million yuan, up 26.67% [4] - The core product, dust mite drops, generated approximately 340 million yuan in revenue in Q3 2025, reflecting a year-on-year growth of 17.5% [4] Market Position - Iwu Biological holds over 80% market share in the domestic allergy treatment sector, positioning itself as a leading player in a market with substantial growth potential [5] - The company benefits from a favorable regulatory environment in Zhejiang Province, which supports the development of innovative drugs and medical devices through financial incentives and streamlined approval processes [2][3] R&D and Product Pipeline - The company is transitioning from a product-driven model to a platform-based approach, with a diverse R&D pipeline that includes new products like the Artemisia pollen sublingual drops, which have shown efficacy in clinical trials [4][5] - Recent innovations, such as the dermatitis diagnostic patch, indicate a robust clinical advancement strategy that supports long-term growth [4]

Group 1: Shareholding Changes - Company Zhaoyi Innovation announced that several directors and senior management personnel plan to reduce their holdings by a total of 249,000 shares, with specific reductions from the vice chairman and general manager, as well as other vice presidents [1] - Company Super Aerospace announced a stock suspension due to its controlling shareholders planning a significant matter that may lead to a change in control [2] - Company Haosai is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [5] Group 2: Major Contracts and Projects - Company Dajin Heavy Industry's wholly-owned subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, which represents 35.41% of the company's audited revenue for 2024 [3] - Company Ruifeng New Materials plans to increase capital by 200 million yuan in a related party to advance a lithium hexafluorophosphate project [6] Group 3: Regulatory Actions - Company Jushi Chemical received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [4] - Company Huosai is also under investigation by the CSRC for similar reasons [5] Group 4: Investment and Acquisitions - Company Gao Neng Environment plans to acquire 45.2% equity in three mining companies [7] - Company Aerospace Electric intends to purchase 32% equity in Shenzhen Aerospace Electric Motor System Co., Ltd. through public bidding [8]

Core Viewpoint - The company has received approval for a clinical trial supplement application for its drug "Artemisia pollen puncture solution" from the National Medical Products Administration [2] Group 1 - The company announced on November 21 that it obtained the approval notification for the clinical trial supplement application [2] - The approval was downloaded from the official website of the National Medical Products Administration [2] - The drug in question is referred to as "Artemisia pollen puncture solution" [2]

Core Viewpoint - The company, Iwu Biologics (300357.SZ), has received approval for a supplementary application for clinical trials of its drug "Artemisia Pollen Puncture Solution" from the National Medical Products Administration, indicating progress in its product development pipeline [1] Group 1 - The approved clinical trial is aimed at diagnosing Type I hypersensitivity diseases related to ragweed pollen allergy through skin prick tests [1]

Core Viewpoint - The company Iwu Biologics (300357.SZ) has received approval for a supplemental application for clinical trials of its drug "Ragweed Pollen Skin Prick Solution," which is aimed at diagnosing type I hypersensitivity diseases related to ragweed pollen allergy [1] Group 1 - The drug is classified as a therapeutic biological product and is formulated as a skin prick reagent [1] - The approved formulation has a total allergen activity of 3500 DU/ml and comes in a 2 ml bottle [1] - The company will fulfill its information disclosure obligations based on the progress of the clinical trials [1]

Core Viewpoint - The company has received approval for a supplementary application for clinical trials of "Artemisia pollen prick solution" from the National Medical Products Administration, allowing for an increase in total allergen activity to 3500 DU/ml with a packaging specification of 2 ml per bottle [1] Group 1 - The company has downloaded the "Approval Notification for Supplementary Application of Drug Clinical Trials" from the National Medical Products Administration [1] - The approved supplementary application pertains to the "Artemisia pollen prick solution" [1] - The new specification allows for a total allergen activity of 3500 DU/ml [1]